Clinical Outcomes of Third-Generation Cephalosporin Definitive Therapy for Bloodstream Infections Due to Enterobacterales with Potential AmpC Induction: A Single-Center Retrospective Study.
AmpC
Enterobacterales
Enterobacteriaceae
antimicrobial resistance
beta-lactamases
cephalosporins
Journal
Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317
Informations de publication
Date de publication:
11 Sep 2023
11 Sep 2023
Historique:
received:
14
07
2023
revised:
05
09
2023
accepted:
08
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
The recommended therapy for severe infections caused by AmpC-inducible Enterobacterales (AmpC-E) typically involves cefepime or carbapenems. In an era of emerging resistance to these antimicrobials, we aim to assess the impact of third-generation cephalosporins (3GCs) vs. alternative antibiotics on clinical outcomes in bloodstream infections (BSIs) due to AmpC-E. We retrospectively included hospitalized adult patients with BSIs caused by 3GC-susceptible AmpC-E between 2012 and 2022, comparing the outcomes of 3GC and non-3GC definitive therapies. The primary outcome was overall treatment failure (OTF), encompassing 90-day all-cause mortality, 90-day reinfection, and 90-day readmission. Secondary outcomes comprised components of the OTF, in-hospital all-cause mortality, and length-of-stay. Within a total cohort of 353 patients, OTF occurred in 46.5% and 41.5% in the 3GC- and non-3GC-therapy groups, respectively (
Identifiants
pubmed: 37764960
pii: pathogens12091152
doi: 10.3390/pathogens12091152
pmc: PMC10537439
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Nat Rev Microbiol. 2019 May;17(5):295-306
pubmed: 30837684
Open Forum Infect Dis. 2019 Jul 1;6(7):
pubmed: 31363762
Antimicrob Agents Chemother. 2008 Mar;52(3):995-1000
pubmed: 18086837
Antimicrob Agents Chemother. 2001 Sep;45(9):2628-30
pubmed: 11502540
Microb Drug Resist. 2021 Mar;27(3):410-414
pubmed: 32808858
J Nat Sci Biol Med. 2015 Jul-Dec;6(2):383-7
pubmed: 26283835
Antimicrob Resist Infect Control. 2017 Jan 21;6:14
pubmed: 28127422
Clin Infect Dis. 2023 Jul 18;:
pubmed: 37463564
J Antimicrob Chemother. 2017 Sep 1;72(9):2410-2417
pubmed: 28637307
Crit Care. 2017 Nov 14;21(1):276
pubmed: 29137682
Clin Infect Dis. 1995 Nov;21(5):1107-13
pubmed: 8589129
Clin Infect Dis. 2004 Sep 15;39(6):812-8
pubmed: 15472813
Ann Intern Med. 1991 Oct 15;115(8):585-90
pubmed: 1892329
Antibiotics (Basel). 2020 Apr 20;9(4):
pubmed: 32326058
J Clin Microbiol. 2011 Aug;49(8):2798-803
pubmed: 21632895
Ann Intensive Care. 2022 Nov 17;12(1):107
pubmed: 36394673
J Antimicrob Chemother. 2018 Jun 1;73(6):1530-1536
pubmed: 29566147
Clin Microbiol Rev. 2009 Jan;22(1):161-82, Table of Contents
pubmed: 19136439
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Open Forum Infect Dis. 2021 Aug 02;8(8):ofab387
pubmed: 34395716
Clin Microbiol Infect. 2015 Jul;21(7):649.e1-10
pubmed: 25882363
Antimicrob Agents Chemother. 2003 Jun;47(6):1882-6
pubmed: 12760862
Antimicrob Agents Chemother. 2018 Sep 24;62(10):
pubmed: 30061284
Antibiotics (Basel). 2020 May 14;9(5):
pubmed: 32423104